The company will develop Lucis’ liquid pipeline products. Source: Shutterstock / Matveev Aleksandr.

Oral liquid medicine manufacturer Rosemont Pharmaceuticals has announced the acquisition of Lucis Pharma.

UK-based Rosemont hopes that this latest acquisition will bolster its portfolio with a pipeline of innovative products and allow it to serve the UK and overseas markets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Rosemont believes this acquisition will allow it to enter the single-use sachet pharmaceutical market, expanding its liquid medicines portfolio in a growing market. In a June statement, Rosemont CEO Howard Taylor highlighted Lucis’ product pipelines and developer relationships as a driver of the acquisition, accelerating Rosemont’s entry into the sachet market.

A Rosemont spokesperson affirmed the company’s enthusiasm for the market, telling Pharmaceutical Technology that single-use sachets offer a greater level of convenience for current and potential patients. The manufacturer also disclosed that it is seeking further acquisitions in this space.

Founded in 2012, Lucis develops and licenses novel and exclusive medicines. It currently offers more than a dozen products across a range of therapeutic areas, with a pipeline of liquid medicines proving particularly attractive to Rosemont.

These offerings will complement over 130 oral liquid medicines currently offered by Rosemont to meet the needs of dysphagic patients.

The company also offers over 50 years of experience in novel, oral liquid medicines. It manufactures over one million litres of bulk liquid annually, equating to four million bottles of liquid medicine.

Liquid medicines are an important avenue of treatment for patients with swallowing difficulties or dysphagia. Most nursing home residents and stroke patients experience dysphagia to some extent. Patients with Parkinson’s disease are particularly affected, together with those with intellectual disabilities. Children are also heavily affected, with 25%-45% of paediatric patients experiencing dysphagia.

According to a GlobalData epidemiology forecast, there will be nearly 190 million cases of dysphagia globally by 2030. China will comprise a majority at almost 120 million cases, followed by India at 35 million. While the markets there are generally well served by local manufacturers, Rosemont plans to establish distribution centres in the Greater Bay Area of China to fill gaps in the market.

GlobalData is the parent company of Pharmaceutical Technology.